CVRx Announces Positive News on Outpatient Payment for Barostim
This proposal follows two other positive developments in the last nine months relating to reimbursement rates. As of Oct. 1, 2024, Barostim was assigned to a higher paying MS-DRG for inpatient procedures. In that same month it was announced that Barostim will transition from Category III to Category I CPT codes for physician payments as of Jan. 1, 2026. These reimbursement updates underscore the clinical value of Barostim and reinforce its role in the heart failure care continuum.
'We appreciate CMS' proposal to keep Barostim in APC 1580, ensuring appropriate payment for the Barostim implant procedure,' said Kevin Hykes, President and CEO of CVRx. 'These reimbursement updates, along with the favorable proposed payment levels included in the recently released physician fee schedule, allow us to continue our progress toward expanding access to Barostim for patients suffering from heart failure with reduced ejection fraction, which we believe will help support its broader market adoption and long-term growth.'
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements about the proposal to maintain the APC for the Barostim implant procedure and progress toward expanded access to Barostim are forward-looking statements. These statements speak only as of the date of this press release and are based on our current expectations and projections about future events, and are subject to a number of known and unknown risks and uncertainties that could cause actual results to differ from our expectations, including the final OPPS rule, which could differ from the proposed rule, following the public comment period, and the actual impact of the APC on actual reimbursement and patient access. These forward-looking statements speak only as of the date of this press release. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Media Contact:Emily MeyersCVRx, Inc.763-416-2853emeyers@cvrx.com
Investor Contact:Mark Klausner or Mike VallieICR Healthcare443-213-0501ir@cvrx.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
From Seattle to Chiba: Okayama University Taps AGC Biologics' Global Pathway for New Therapeutic
SEATTLE & CHIBA, Japan--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a new service agreement with Okayama University, a prominent national university in Japan. This project will leverage AGC Biologics' global network, with the mammalian cell line development capabilities in Seattle, USA, and cGMP mammalian manufacturing facility in Chiba, Japan, working together to advance a new therapeutic program for the university. Under the agreement, AGC Biologics will perform cell line development with its proprietary CHEF1™ expression platform in Seattle. CHEF1's track record includes the production of more than 55 different molecules and the development of five commercial products brought to market. The program will then be transferred to the company's facility in Chiba for process development for clinical trials in 2026. The collaboration between its Asian and U.S. sites highlights AGC Biologics' ability to offer research institutions a seamless, global pathway from early-stage development to clinical manufacturing. 'This project is a perfect example of our winning global blend, combining the world-class cell line development excellence in Seattle with the most-advanced cGMP-compliant mammalian cell culture manufacturing capabilities available in Japan,' said Susumu Zen-in, General Manager of AGC Biologics' Chiba facility. 'By providing a high level of global standard expertise and an emphasis on flexibility, we're able to effectively serve prestigious academic institutions like Okayama University working to bring vital new medicines to patients.' Okayama University selected AGC Biologics for its integrated global network and its unique position in Japan. The Chiba facility offers mammalian cell culture-based services to serve the needs of customers from Japan and the surrounding regions. This partnership underscores AGC Biologics' commitment to supporting academic and research institutions by providing the technical creativity and specialized services needed to solve complex challenges and advance important new therapies. To learn more about AGC Biologics' global network of services, visit About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit
Business Wire
an hour ago
- Business Wire
UFP Industries to Report Second Quarter 2025 Results on Monday, July 28, 2025
GRAND RAPIDS, Mich.--(BUSINESS WIRE)--UFP Industries (Nasdaq: UFPI) will announce second quarter 2025 results after the market close on Monday, July 28, 2025. The company will host a conference call to discuss these results on Tuesday, July 29, 2025, at 9 a.m. Eastern Time. A live audio webcast of the call along with supporting materials will be available on the UFP Industries Investor Relations website at and can also be directly by accessing the link here. A webcast replay will be available on the company's website for at least 90 days following the call. UFP Industries, Inc. UFP Industries, Inc. is a holding company whose operating subsidiaries – UFP Packaging, UFP Construction and UFP Retail Solutions – manufacture, distribute and sell a wide variety of value-added products used in residential and commercial construction, packaging and other industrial applications worldwide. Founded in 1955, the company is headquartered in Grand Rapids, Mich., with affiliates in North America, Europe, Asia and Australia. UFP Industries is ranked #128 on Industry Week's list of America's Largest Manufacturers. For more about UFP Industries, go to
Yahoo
an hour ago
- Yahoo
OFS Capital Corporation Prices Public Offering of $60,000,000 7.50% Notes Due 2028
CHICAGO, July 16, 2025--(BUSINESS WIRE)--OFS Capital Corporation (the "Company" or "OFS Capital") (Nasdaq: OFS) announced today that it has priced a registered public offering of $60,000,000 aggregate principal amount of its 7.50% notes due 2028 (the "Notes") which will result in net proceeds to the Company of approximately $58,500,000 (or approximately $67,320,000 if the underwriters fully exercise the overallotment option described below) based on a public offering price of 100% of the aggregate principal amount of the Notes, after deducting payment of underwriting discounts and commissions and estimated offering expenses of $300,000 payable by the Company. The Notes will mature on July 31, 2028 and may be redeemed in whole or in part at any time, or from time to time, at the Company's option on or after July 31, 2026. The Notes will bear interest at a rate of 7.50% per year, payable quarterly on January 31, April 30, July 31, and October 31 of each year, beginning on October 31, 2025. The Company has also granted the underwriters a 30-day option to purchase an additional $9,000,000 aggregate principal amount of Notes to cover overallotments, if any. The offering is subject to customary closing conditions and is expected to close on July 23, 2025. The Company has submitted an application for the Notes to be listed and trade on The Nasdaq Global Select Market under the trading symbol "OFSSO". If approved for listing, the Company expects the Notes to begin trading within 30 days from the original issue date. The Company intends to use the net proceeds from this offering to partially redeem its 4.75% Notes due 2026, which mature on February 10, 2026. As of July 14, 2025, the Company had approximately $125.0 million aggregate principal amount outstanding of its 4.75% Notes due 2026. On July 11, 2025, the Company issued notices to the holders of the 4.75% Notes due 2026 regarding the exercise of its option to redeem a portion of the issued and outstanding amount of such notes. On August 11, 2025, the Company will redeem $25.0 million in aggregate principal amount of its 4.75% Notes due 2026, plus accrued interest and any required make-whole premium payment. Lucid Capital Markets, LLC and Goldman Sachs & Co. LLC are acting as joint book-running managers of this offering. Investors are advised to carefully consider the investment objective, risks and charges and expenses of the Company before investing. The preliminary prospectus supplement, dated July 16, 2025, and accompanying prospectus, dated May 29, 2024, each of which has been filed with the Securities and Exchange Commission, contain a description of these matters and other important information about the Company and should be read carefully before investing. The information in the preliminary prospectus supplement, the accompanying prospectus and this press release is not complete and may be changed. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities in this offering or any other securities nor will there be any sale of these securities or any other securities referred to in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. A shelf registration statement relating to these securities is on file with, and has been declared effective by, the SEC. Before you invest, you should read the Preliminary Prospectus, the accompanying prospectus, and other documents the Company has filed with the SEC for more complete information about the Company and this offering. You may obtain these documents for free by visiting EDGAR on the SEC web site at Alternatively, the Company, any underwriter or any dealer participating in the offering will arrange to send you the Preliminary Prospectus and the accompanying prospectus if you request it from Lucid Capital Markets, LLC, 570 Lexington Ave, 40th Floor, New York, New York 10022 or Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, New York 10282, email: Prospectus-ny@ tel: 1-866-471-2526. About OFS Capital Corporation OFS Capital Corporation is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company. OFS Capital's investment objective is to provide stockholders with both current income and capital appreciation primarily through debt investments and, to a lesser extent, equity investments. OFS Capital invests primarily in privately held middle-market companies in the United States, including lower-middle-market companies, targeting investments of $3 million to $20 million in companies with annual EBITDA between $5 million and $50 million. OFS Capital offers flexible solutions through a variety of asset classes including senior secured loans, which includes first-lien, second-lien and unitranche loans, as well as subordinated loans and, to a lesser extent, warrants and other equity securities. OFS Capital's investment activities are managed by OFS Capital Management, LLC, an investment adviser registered under the Investment Advisers Act of 19401, as amended, and headquartered in Chicago, Illinois, with additional offices in New York and Los Angeles. FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements that involve substantial risks and uncertainties, including the future operating results of OFS Capital. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in OFS Capital's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission under the section "Risk Factors," and in "Part II, Item 1A. Risk Factors" in OFS Capital's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as other documents that may be filed by OFS Capital from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. OFS Capital is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 1 Registration does not imply a certain level of skill or training OFS® and OFS Capital® are registered trademarks of Orchard First Source Asset Management, Capital Management™ is a trademark of Orchard First Source Asset Management, LLC. View source version on Contacts INVESTOR RELATIONS CONTACT: Steve Altebrando847-734-2084investorrelations@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
